← Browse by Condition
Medical Condition
her2 low hormone receptor positive breast cancer
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 2, Phase 2
NCT07287917 Phase 1, Phase 2
Recruiting
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Enrollment
92 pts
Location
United States
Sponsor
Aminex Therapeutics, Inc.
NCT06832202 Phase 2
Recruiting
A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
Enrollment
50 pts
Location
China
Sponsor
Shanghai Henlius Biotech